Sort
326,823 grants matching “clinical trial”
Multi-site, double-blind, randomized-controlled, efficacy trial of the Transdiagnostic Intervention for Sleep and Circadian Dysfunction for depression symptoms in older adults with high suicide risk
$2,559,951Stephen F Smagula · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · MH
HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027
$2,559,665Linda-Gail Bekker · University Of Cape Town · UM1 · FY2022 · AI
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.
$2,559,183Manfred Windisch · Pharmatrophix, Inc. · R01 · FY2019 · AG
Center for Translational Cancer Nanomedicine
$2,558,928Vladimir P Torchilin · Northeastern University · U54 · FY2011 · CA
Center for the Study of Aphasia Recovery (C-STAR)
$2,558,826Julius Fridriksson · University Of South Carolina At Columbia · P50 · FY2021 · DC
Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network: Statistics and Data Management Core
$2,558,426Janet Ellen Dancey · Queen'S University At Kingston · U10 · FY2023 · CA
Use of a GLP-1 Agonist to Treat Opioid Use Disorder in Rats and Man
$2,557,628Patricia Sue Grigson · Pennsylvania State Univ Hershey Med Ctr · UG3 · FY2020 · DA
Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases
$2,557,500Jiang He · Tulane University Of Louisiana · P20 · FY2016 · GM
Pulmonary innate immune activation for bioterror defense
$2,557,168Coley Pharmaceutical Group, Inc. · U01 · FY2005 · AI
Gulf South Minority/Underserved Clinical Trials Network (Gulf South M/U CTN)
$2,557,045Augusto C Ochoa · Lsu Health Sciences Center · UG1 · FY2024 · CA
Combination Therapies to Defeat Melanoma Resistance
$2,556,789Antoni Ribas · University Of California Los Angeles · P01 · FY2022 · CA
Combination Therapies to Defeat Melanoma Resistance
$2,556,789Antoni Ribas · University Of California Los Angeles · P01 · FY2023 · CA
Immunobiology and Immune Therapyfor Merkel Cell Carcinoma
$2,556,762Paul Nghiem · University Of Washington · P01 · FY2023 · CA
Development of TNX-1300 (Double Mutant Cocaine Esterase) for the Treatment of Life-Threatening Cocaine Intoxication
$2,556,716Gregory M Sullivan · Tonix Pharmaceuticals, Inc. · U01 · FY2022 · DA
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS
$2,556,401Bruce R. Blazar · University Of Minnesota · UL1 · FY2011 · RR
Vascular Subphenotypes of Lung Disease
$2,556,023Mark Thomas Gladwin · University Of Pittsburgh At Pittsburgh · P01 · FY2012 · HL
Pharmacogenomics and Risk of Cardiovascular Disease
$2,555,469Ronald M Krauss · Children'S Hospital & Res Ctr At Oakland · U19 · FY2014 · HL
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)
$2,555,380Geoffrey I Shapiro · Dana-Farber Cancer Inst · UM1 · FY2023 · CA
Lentiviral Gene Therapy for Sickle Cell Disease and Immunodeficiency Disorders
$2,555,299Brian P Sorrentino · St. Jude Children'S Research Hospital · P01 · FY2014 · HL
A Dose Escalation Study of Low Dose Aspirin for the Prevention of Recurrent Preterm Birth
$2,555,013Rebecca Gersnoviez Clifton · George Washington University · U01 · FY2024 · HD
GENERAL CLINICAL RESEARCH CENTER
$2,554,946Alan M Miller · Tulane University Of Louisiana · M01 · FY2006 · RR
Novel SIVsmm strains for analysis of mucosal transmission and vaccine protection
$2,554,863George M Shaw · University Of Pennsylvania · P01 · FY2011 · AI
SPORE in Genitourinary Cancer
$2,554,804Colin P Dinney · University Of Tx Md Anderson Can Ctr · P50 · FY2006 · CA
HYPOTHERMIA DURING INTRACRANIAL ANEURYSM SURGERY
$2,554,263University Of Iowa · R01 · FY2002 · NS
Co-occurring ADHD in young children with ASD: Precursors, detection, neural signatures, and early treatment
$2,554,044Geraldine Dawson · Duke University · P50 · FY2019 · HD